Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…
Government Regulation You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is a highly developed economy to start with; it is a very established market, with a very good healthcare system. The…
Baltic You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see for AstraZeneca in pushing this development forward? AstraZeneca has a significant R&D presence in Sweden. We currently have more than 2,300 researchers at our…
AstraZeneca Australia You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at the overall market, the biggest changes have been the various reforms to the Pharmaceutical Benefits Scheme (PBS). PBS reform started…
AstraZeneca Poland You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given when you took office? I would not say that I have been given a mission, but that I have been…
AstraZeneca Brazil What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a very productive combination of excellent products being worked by talented people with the right level of investment. This is what…
AstraZeneca Turkey Even though you have delivered strong results in most of the markets you have been appointed, this is your first assignment as the head of a subsidiary. For a man and manager who has experienced only successes in his life and career, what were the new challenges of leading a…
AstraZeneca Mexico There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place. In your view, what have been the most significant changes, and how have they affected the market? The biggest shift…
AstraZeneca Levant You have been Levant manager for 5 years now and the one that set up AstraZeneca in Jordan. How challenging has it been to establish the company in the Jordanian market? We needed to have full comprehensive understanding of the market and its different sectors and we needed to understand…
AstraZeneca Thailand Dr. Seeto, this is your first head of country position for AZ! Looking back at your first year-and-a-month, what have been the highlights and the key lessons learnt? Firstly, leading the Thai country organization has been a real privilege and honor. Looking back, I am proud of how the country…
AstraZeneca Russia You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in Kaluga. What are the implications of this project for AstraZeneca and why was it important for you to invest here?…
AstraZeneca Hungary The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in Hungary? I would say that it has become an extremely difficult environment to operate in. There is a myth that…
See our Cookie Privacy Policy Here
